Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 9:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 1,450 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety in Healthy Adults Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

PK And Safety Study Of PF-04171327 In Healthy Japanese And Western Subjects In Fasting And Fed Conditions

NCT01362673
View directory record Official record
Conditions
Healthy
Interventions
PF-04171327, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2011 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety and Immune Response of a Vaccine Against Influenza in Healthy Younger and Older Adults

NCT05823974
View directory record Official record
Conditions
Influenza, Human
Interventions
F2C22C/DL001Z, F2B22A/DL001Z, F2B22B/DL001Z, F2B22C/DL001Z, F2B22D/DL001Z, F2B22E/DL001Z, F2F22A/DL001Z, F2F22B/DL001Z, F2F22C/DL001Z, F2F22D/DL001Z, F2F22E/DL001Z, Control 1, F2F23D/DL001Z-NH, F2F23A/DL001Z-NH, F2F23B/DL001Z-NH, Control 2, F2F23C/DL001Z-NH, Control 3, F2F22F/DL001Z
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
24
States / cities
Hialeah, Florida • Miami, Florida • Chicago, Illinois + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating Heterologous-Insert Prime-Boost HIV Vaccine Regimens in HIV-Uninfected Adults

NCT01095224
View directory record Official record
Conditions
HIV Infections
Interventions
rAd35 Env A, rAd5 Env A, rAd5 Env B
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2016
U.S. locations
8
States / cities
Birmingham, Alabama • San Francisco, California • Decatur, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2021 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluate the Safety and PK of Proellex® in Female Patients With Impaired Hepatic Function and Healthy Adults

NCT00741273
View directory record Official record
Conditions
Impaired Liver Function
Interventions
Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 62 Years · Female only
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 28, 2014 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety of Repeated Doses of GSK189075 and WELLBUTRIN SR in Healthy Male Subjects

NCT00625859
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK189075, Bupropion, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of E2086 in Healthy Adult Participants

NCT06481488
View directory record Official record
Conditions
Healthy Volunteers
Interventions
E2086, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study to Evaluate the Contact Sensitizing Potential of Topically Applied ZuraPrep™ and ZuraPrep™ Without IPA

NCT02160587
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Chloraprep, 0.9% Physiological Saline, ZuraPrep without IPA
Drug · Other
Lead sponsor
Zurex Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Bozeman, Montana
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 30, 2026, 9:24 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine in Healthy Adults

NCT06745921
View directory record Official record
Conditions
West Nile Viral Infection
Interventions
HydroVax-001B WNV, Placebo, Sodium Chloride, 0.9%
Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Single or Repeat Dose of G03-52-01 in Adult Subjects

NCT05348993
View directory record Official record
Conditions
Healthy, Botulinum Toxin
Interventions
G03-52-01, Placebo
Drug
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 65 Years
Enrollment
622 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
15
States / cities
Mobile, Alabama • Tempe, Arizona • Fort Myers, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Chimeric Hemagglutinin mRNA Vaccine Candidates

NCT07703514
View directory record Official record
Conditions
Influenza
Interventions
cH15/3, cH4/3, cH5/1N1, cH8/1N1, Saline
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of Novel Types 1 and 3 Oral Poliomyelitis Vaccines

NCT04529538
View directory record Official record
Conditions
Poliomyelitis
Interventions
Novel Oral Polio Vaccine Type 1 (nOPV1), Novel Oral Polio Vaccine Type 3 (nOPV3), Sabin Monovalent Oral Polio Vaccine Type 1 (mOPV1), Sabin Monovalent Oral Polio Vaccine Type 3 (mOPV3)
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Baltimore, Maryland • Lebanon, New Hampshire • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Investigational Study to Evaluate the Safety and Tolerability of Single and Multiple Ascending Doses of A-005

NCT07442149
View directory record Official record
Conditions
Healthy Volunteer
Interventions
A-005, Placebo
Drug
Lead sponsor
Alumis Inc
Industry
Eligibility
19 Years to 55 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of TAK-105 in Healthy Adults

NCT04964258
View directory record Official record
Conditions
Healthy Volunteers
Interventions
TAK-105-a, TAK-105-a Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Tempe, Arizona • Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2024 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993

NCT06226454
View directory record Official record
Conditions
Pain
Interventions
VX-993, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Oct 30, 2026, 9:24 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose Study of DTI-117 Given Intramuscularly in Healthy Participants.

NCT07882472
View directory record Official record
Conditions
Healthy Adult
Interventions
DTI-117, Placebo
Drug
Lead sponsor
Dignify Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea

NCT01382095
View directory record Official record
Conditions
Escherichia Coli Infection
Interventions
Recombinant fimbrial adhesin dscCfaE, Modified E. coli heat labile enterotoxin LTR192G
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional

A Multiple Ascending Dose Study in Healthy Volunteers and Patients With Alzheimer's Disease

NCT05804383
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BMS-984923, Placebo
Drug
Lead sponsor
Allyx Therapeutics
Industry
Eligibility
50 Years to 80 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
New Haven, Connecticut • West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients

NCT04350177
View directory record Official record
Conditions
Healthy Elderly, Parkinson Disease
Interventions
IkT-148009, Placebo
Drug
Lead sponsor
ABLi Therapeutics, Inc.
Industry
Eligibility
55 Years to 70 Years
Enrollment
101 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
4
States / cities
Long Beach, California • Hallandale, Florida • Farmington Hills, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2025 · Synced Oct 30, 2026, 9:24 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

First Time in Human Study of Long Acting VH4524184 Formulations

NCT06310551
View directory record Official record
Conditions
HIV Infections
Interventions
Oral VH4524184, VH4524184 Formulation A SC, Placebo Formulation A SC, rHuPH20, VH4524184 Formulation B SC, Placebo Formulation B SC, VH4524184 Formulation A IM, Placebo Formulation A IM, VH4524184 Formulation B IM, Placebo Formulation B IM
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
3
States / cities
Lenexa, Kansas • San Antonio, Texas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)

NCT06024239
View directory record Official record
Conditions
Healthy Volunteers, Generalized Anxiety Disorder (GAD), Bipolar Disorder (BPD)
Interventions
ABBV-932, Placebo for ABBV-932
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
3
States / cities
Los Alamitos, California • Grayslake, Illinois • Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196

NCT04914936
View directory record Official record
Conditions
Healthy Participants
Interventions
ACP-196, Calcium carbonate, Omeprazole, Rifampin
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 7, 2021 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic, Immunogenicity, and Safety Evaluation of Pegfilgrastim TPI-120 in Healthy Adults

NCT07416955
View directory record Official record
Conditions
Healthy Volunteer
Interventions
TPI-120 Pre-Filled Syringe 6 mg/0.6 mL
Biological
Lead sponsor
Kashiv BioSciences, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Dose-Escalation Study to Evaluate Tolerability, Safety & PK of INO-8875 in Healthy Older-Adult Volunteers

NCT01123772
View directory record Official record
Conditions
Health
Interventions
INO-8875, Placebo control
Drug · Other
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
35 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 30, 2026, 9:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product

NCT03698305
View directory record Official record
Conditions
Healthy Subjects
Interventions
ASP5354, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 30, 2026, 9:24 PM EDT